TAKEDA PHARMACEUTICAL CO LTD (TAK) Form 6-K — Oct 29, 2026
Takeda reported H1 FY2026 (six months ended September 30, 2026) revenue of JPY 2,407.0 billion, up 8.4% at actual exchange rates but down 1.0% at constant exchange rates, with the AER increase driven primarily by yen depreciation. IFRS net profit attributable to owners surged 171.8% to JPY 305.6 billion and basic EPS rose to JPY 192.53, largely on lower amortization/impairment charges (JPY 218.5 billion vs JPY 336.8 billion) and an 80.4% drop in income tax expense from deferred tax benefits.
Key figures
- Eps
- 192.53
- Revenue
- 2406997000000
- Net Income
- 305716000000
- Revenue Yoy
- +8.4% AER / -1.0% CER
- Total Assets
- 15271498000000
- Cash Position
- 418533000000
- Core eps
- JPY 308 (+10.5% AER, -1.2% CER)
- Diluted eps
- JPY 189.52
- Rd expenses
- JPY 338.6 billion (+10.9% AER)
- Core revenue
- JPY 2,407.0 billion (-1.0% CER)
- Entvio sales
- JPY 541.7 billion (+13.0% AER, +2.7% CER)
- Shares issued
- 1602218559
- Operating profit
- JPY 406.7 billion (+60.4% AER, +45.0% CER)
- Trintellix sales
- JPY 71.3 billion (+25.2% AER)
- Dividends paid h1
- JPY 158,494 million (JPY 100.00/share)
- Profit before tax
- JPY 318.7 billion (+78.2% AER)
- Operating cash flow
- JPY 431.9 billion (-JPY 161.8 billion YoY)
- Core operating profit
- JPY 710.6 billion (+0.7% CER)
- Interim dividend total
- JPY 163,406 million
- Interim dividend per share
- JPY 102.00
- Restructuring expenses increase
- JPY 52.4 billion (transformation program)
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.